BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Apr 11, 2011
 |  BC Week In Review  |  Company News  |  Other News

Celgene, Lannett cancer, generics news

The U.S. District Court of the Eastern District of Pennsylvania denied a motion by Celgene to dismiss a case brought by generics company Lannett seeking to require Celgene to provide Lannett with enough Thalomid thalidomide to conduct bioequivalence studies. The studies are necessary to support an ANDA submission for a generic version of the small molecule alpha-(N-phthalimido) glutarimide immunomodulatory agent, which is approved in the EU and U.S. to treat multiple myeloma (MM). Thalomid is available through Celgene's STEPS program, a restricted distribution system required...

Read the full 412 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >